Glenn
This sure sounds like WJCI:
THE BLAST: The Scoop
August 18, 2004
I've beaten Wall Street to a major story.
Last Friday, I toured the labs of a small, early-stage West Coast
technology company - a company I've been following for close to five years.
Professionally, I know several of the scientists and executives here
well. That's why I was the first outsider to see a major scientific advance.
This situation could be worth as much as two billion dollars per year
for this small cap firm - a stunning development that could help it corner the market for this product.
After seeing this development firsthand, I have only one thing to say. I
feel certain this company could well be the next Qualcomm (Nasdaq:
QCOM).
Like Qualcomm, this small company will have a monopoly on a device used by tens of millions of people every year.
It's also worth noting that early investors in Qualcomm's CDMA wireless
technology have gains of 9,877%.
Unlike Qualcomm, this company isn't a giant valued at $28 billion. Not
even close.
Today, this small company is worth less than $250 million, offering similar upside gains as Qualcomm.
Six months ago, I took an economic risk analyst with me to see this high
tech company. My friend's a smart guy, too. He's a graduate of a top-ten
business school, and he was heavily recruited by IBM and Microsoft right out of college.
His advice to me about this small cap firm -- "BUY."
I believe this is the best high tech company for investors, anywhere.
What I saw last Friday validates all of its technology. The technical hurdles
have been solved.
I'm sending my full report on this situation to Diligence members today.
With a scoop like this, I'm sure you understand: I can only share this
valuable information with my subscribers.
If you join Diligence today, I'll send you the "scoop" by electronic
mail.
You can choose either a yearly or quarterly subscription. This includes
monthly conference calls and e-mail updates on all the Diligence
companies.
Also when you join, there's very little risk. Read my latest update (the one I just told you about) and read our published research on this company. If you don't think Diligence is the best small cap research available, we'll give you a prorated refund based on the unused portion of your subscription.
Here's how Diligence works: we cut the risk for investors in emerging
new companies by bringing you expert, in-depth research.
This is the kind of research I doubt you'll ever get from your broker.
For example, with the firm I told you about, I've toured the labs with a
Master Electrical Engineer -- a senior designer of high tech devices.
Another Diligence expert we've worked with is the past president of a
major engineering society. He's worked for Sony, NEC and RCA. Plus, he's a Ph.D. in optics.
So, add these guys to the dozen medical school professors we consult
with for Diligence, and you'll understand why I believe we're the best
research service for investors in new drugs and new technology.
But that's only half the story. What really matters for investors are
returns.
No matter how powerful a technology is, it's worthless if you can't sell
it.
That's why we analyze the markets -- and the competition -- before we
add a recommendation to Diligence. That's also why we bring finance experts to Diligence, too.
The next monthly Diligence conference call is on Monday, August 23rd.
But I couldn't wait until the call for this scoop.
Due to the scope of the development I saw last Friday, early investors
stand to make significant gains here. That's why I call this report "THE MONEY MAKER".
Sign up for Diligence to learn more.
Click here to sign up for Diligence. |
